Previous 10 | Next 10 |
REDWOOD CITY, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a multi - year agreement with Tate & Lyle, a global provider of food ingredients and solutions, for the supply and licensing of novel Co...
REDWOOD CITY, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2019 financial results after market close on Monday, May 6, 2019. Codexis management will hold an investment community co...
REDWOOD CITY, Calif., April 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that Jim Lalonde, Ph.D., Senior Vice President of Research and Development, will resign effective May 31, 2019 to pursue other interests. “Jim ha...
The FDA has signed off on a Phase 1/2 clinical trial, pheNIX, evaluating Homology Medicines' ( FIXX +0.4% ) gene therapy candidate HMI-102 in adults with a rare inherited disorder called phenylketonuria (PKU), referred to as an inborn error of metabolism. More news on: Homology Medicin...
REDWOOD CITY, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in two upcoming investment conferences: Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12 ...
Start Time: 16:30 End Time: 17:22 Codexis, Inc. (CDXS) Q4 2018 Earnings Conference Call February 26, 2019, 16:30 PM ET Company Participants John Nicols - President and CEO Gordon Sangster - SVP and Chief Financial Officer Jody Cain - LHA Conference Call Participants Bra...
The following slide deck was published by Codexis, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Codexis (NASDAQ: CDXS ): Q4 Non-GAAP EPS of $0.03 beats by $0.05 ; GAAP EPS of -$0.01 beats by $0.02 . More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2018 revenues of $61 million include a 50% increase in R&D revenue Introduces 2019 financial guidance Conference call begins at 4:30 pm Eastern time today Accompanying slide presentation available on Investor section of company website REDWOOD CITY, Calif., Feb. 26, 20...
REDWOOD CITY, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of Business Development and Marketing. Heilmann brings to Codexis more than 30 years of leadersh...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...